I agree with you. The main problem with Mayne's generic business was that a significant proportion was landed with the TEVA acquisition.
Generics of their own products like doxycycline have protected their market share, and there are probably others doing well too.
I agree with you. The main problem with Mayne's generic business...
-
- There are more pages in this discussion • 58 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.65 |
Change
-0.130(2.72%) |
Mkt cap ! $395.5M | |||
| Open | High | Low | Value | Volume |
| $4.72 | $4.76 | $4.56 | $825.4K | 176.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1960 | $4.62 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.68 | 123 | 1 |
View Market Depth
| Last trade - 16.10pm 04/09/2024 (20 minute delay) ? |
| MYX (ASX) Chart |